Literature DB >> 21477664

A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices.

Adam J Schwarz1, Lino Becerra, Jaymin Upadhyay, Julie Anderson, Richard Baumgartner, Alexander Coimbra, Jeff Evelhoch, Richard Hargreaves, Brigitte Robertson, Smriti Iyengar, Johannes Tauscher, David Bleakman, David Borsook.   

Abstract

Functional magnetic resonance imaging (fMRI) experiments are more complex compared with standard radiological imaging, involving additional data streams and hardware along with complex analysis methods. Here, we propose guidelines based around mitigating risks associated with the complexities of the technique at the level of the individual imaging protocol, including workable and effective quality assurance/quality control procedures and rigorous, predefined, analysis pipelines. Our aim is to provide a framework for 'good imaging practice' (GIP), enabling these requirements to be addressed at an appropriate level of detail. The development of a procedural framework for GIP in pharmaceutical fMRI studies could lead to greater acceptance of the method within industry and facilitate validation and, eventually, qualification of the technique as an imaging biomarker.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21477664     DOI: 10.1016/j.drudis.2011.03.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  9 in total

Review 1.  The role of machine learning in neuroimaging for drug discovery and development.

Authors:  Orla M Doyle; Mitul A Mehta; Michael J Brammer
Journal:  Psychopharmacology (Berl)       Date:  2015-05-28       Impact factor: 4.530

Review 2.  Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.

Authors:  Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven
Journal:  Hum Brain Mapp       Date:  2017-02-01       Impact factor: 5.038

Review 3.  Lost but making progress--Where will new analgesic drugs come from?

Authors:  David Borsook; Richard Hargreaves; Chas Bountra; Frank Porreca
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

Review 4.  The role of fMRI in drug development.

Authors:  Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins
Journal:  Drug Discov Today       Date:  2017-11-15       Impact factor: 7.851

Review 5.  fMRI as an outcome measure in clinical trials: A systematic review in clinicaltrials.gov.

Authors:  Alaleh Sadraee; Martin Paulus; Hamed Ekhtiari
Journal:  Brain Behav       Date:  2021-03-04       Impact factor: 2.708

6.  Investigation of cross-species translatability of pharmacological MRI in awake nonhuman primate - a buprenorphine challenge study.

Authors:  Stephanie Seah; Abu Bakar Ali Asad; Richard Baumgartner; Dai Feng; Donald S Williams; Elaine Manigbas; John D Beaver; Torsten Reese; Brian Henry; Jeffrey L Evelhoch; Chih-Liang Chin
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

7.  Comparison of test-retest reliability of BOLD and pCASL fMRI in a two-center study.

Authors:  James W Ibinson; Andrea G Gillman; Vince Schmidthorst; Conrad Li; Vitaly Napadow; Marco L Loggia; Ajay D Wasan
Journal:  BMC Med Imaging       Date:  2022-04-03       Impact factor: 1.930

8.  No effect of a dopaminergic modulation fMRI task by amisulpride and L-DOPA on reward anticipation in healthy volunteers.

Authors:  Oliver Grimm; Magdalena Nägele; Lea Küpper-Tetzel; Moritz de Greck; Michael Plichta; Andreas Reif
Journal:  Psychopharmacology (Berl)       Date:  2020-11-02       Impact factor: 4.530

9.  Use of functional imaging across clinical phases in CNS drug development.

Authors:  D Borsook; L Becerra; M Fava
Journal:  Transl Psychiatry       Date:  2013-07-16       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.